---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-078511"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2026-06-29T12:11:25+00:00"
generated_at: "2026-06-29T12:15:25.403918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Replimune reports Q4 loss of $73.7M; FDA accepts RP1 BLA resubmission for advanced melanoma

## Summary
- Net loss $73.7M in Q4 FY2026; full-year net loss $313.9M.
- FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA Aug 2, 2026, advisory cttee in late July.
- Cash $268.9M at March 31, 2026; expected runway into Q1 calendar 2027.
- IGNYTE-3 (Phase 3) and REVEAL (Phase 2/3) trials enrolling; REVEAL Phase 2/3 transition expected Q1 2027.
- ASCO 2026: RP1+nivo 3-yr OS 47.8%, median OS 32.9 mos; RP2 19% ORR in solid tumors.

## SEC filing metadata
- accession: 0001104659-26-078511
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2026-06-29T12:11:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/0001104659-26-078511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-078511
- JSON: https://secwatch.observer/filing/0001104659-26-078511.json
- Plain text: https://secwatch.observer/filing/0001104659-26-078511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.